Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III L19TNF (Onfekafusp alfa) plus doxorubicin vs doxorubicin in advanced or metastatic soft tissue sarcoma
2016-003239-38Phase 3Active
- Sponsor
- Philogen
- Start
- Aug 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of onfekafusp alfa in soft tissue sarcoma (STS), sponsored by Philogen. Started Aug 2016; status: active.
02
Drugs
onfekafusp alfa
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2016-003239-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003239-38.